Retrospective Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Jan 26, 2021; 9(3): 540-551
Published online Jan 26, 2021. doi: 10.12998/wjcc.v9.i3.540
Table 1 Clinical immune cell data of patients in the primary cohort
Variables
Laryngeal benign lesion
Laryngeal premalignant lesion
Laryngeal malignant lesion
P value
Age, yr50.58 ± 8.6659.91 ± 9.3661.67 ± 9.58< 0.001
Gender, male, n (%)37 (74.0%)52 (96.3%)52 (100%)< 0.001
Smokers, n (%)14 (28.0%)18 (33.3%)29 (55.8%)0.009
Smoke index123.66 ± 245.44235.74 ± 424.28484.31 ± 447.77< 0.001
Drinkers, n (%)6 (12.0%)9 (16.7%)14 (26.9%)0.140
Drinker index1.40 ± 4.852.43 ± 7.214.37 ± 8.380.096
Lymphocytes, %33.30 ± 9.0229.89 ± 9.3729.66 ± 8.570.077
Monocytes, %6.86 ± 3.476.73 ± 1.417.80 ± 2.360.064
Neutrophils, %57.86 ± 9.6160.25 ± 11.0859.95 ± 8.820.414
NLR1.98 ± 1.022.43 ± 1.492.31 ± 1.090.158
LMR5.29 ± 1.824.50 ± 1.334.24 ± 2.260.012
CD3+ T cells, %68.48 ± 8.4162.12 ± 12.0061.82 ± 8.930.001
CD8+ T cells, %25.77 ± 7.8323.64 ± 7.8223.30 ± 7.180.210
CD4+ T cells, %39.13 ± 7.1635.09 ± 8.2136.11 ± 9.270.039
NK cells, %17.35 ± 8.7125.40 ± 12.6524.80 ± 9.21< 0.001
B cells, %13.46 ± 4.1411.51 ± 4.2912.31 + 6.630.157
CD4/CD8+ T cell ratio1.71 ± 0.721.64 + 0.631.78 + 0.940.629
NK/CD3+ T cell ratio0.27 ± 0.200.47 ± 0.450.44 ± 0.220.003
NK/CD4+ T cell ratio0.46 ± 0.290.85 ± 0.780.79 ± 0.420.001
NK/CD8+ T cell ratio0.75 ± 0.731.28 ± 1.351.23 ± 0.740.014
Table 2 Circulating immune features for prediction of laryngeal malignant lesion
Intercept and variables
β1
Odds ratio (95%CI)
P value
Intercept-5.500< 0.0001
Monocytes, %1.2352.351 (1.258-10.066)0.019
CD8+ T cells, %2.1543.303 (2.562-33.856)< 0.001
CD4+ T cells, %2.7012.730 (2.422-123.774)< 0.001
B cells, %1.4642.315 (1.320-16.195)0.021
CD4/CD8+ T cell ratio2.4252.004 (1.413-247.045)0.045